Considerations For The Use Of Stable Producer Lines In The Manufacturing Of Lentiviral Vectors

In an introductory post on lentiviral vector (LVV) manufacturing for cell and gene therapies (CGTs) we touched upon the challenges with transfection-based protocols for producing LVVs at large scale. Clinical and commercial-scale processes for the manufacture of LV remain based on methods adapted from the basic research laboratory. Each of step requires optimization to allow for process scale-up and maximal recovery of functional virus, free of contaminants. The main challenge for optimization is how to effectively translate protocols that are reliable and reproducible at small scale to a scale compatible with commercial product manufacture. Here we will take a closer look at the use of stable producer cell lines as an alternative to transient transfection for the manufacture of LVVs.